Association of Therapies for Axial Spondyloarthritis on the Risk of Hip and Spine Fractures

IF 11.4 1区医学 Q1 RHEUMATOLOGY

Arthritis & Rheumatology Pub Date : 2024-12-16 DOI:10.1002/art.43082

Devin Driscoll, Navya George, Christine Peloquin, S. Reza Jafarzadeh, Jean W. Liew, Maureen Dubreuil

引用次数: 0

Abstract

People with axial spondyloarthritis (axSpA) have increased fracture risk relative to the general population, possibly related to chronic inflammation. We assessed the impact of treatment with tumor necrosis factor inhibitors (TNFi) and non-biologic conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) on hip and spine fractures in axSpA, relative to nonsteroidal anti-inflammatory drugs (NSAIDs).

查看原文本刊更多论文

与普通人群相比，轴性脊柱关节炎（axSpA）患者的骨折风险更高，这可能与慢性炎症有关。我们评估了肿瘤坏死因子抑制剂（TNFi）和非生物常规合成改善病情抗风湿药（csDMARDs）治疗相对于非甾体抗炎药（NSAIDs）对轴性脊柱关节炎患者髋部和脊柱骨折的影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Arthritis & Rheumatology RHEUMATOLOGY-

CiteScore

20.90

自引率

3.00%

发文量

371

期刊介绍： Arthritis & Rheumatology is the official journal of the American College of Rheumatology and focuses on the natural history, pathophysiology, treatment, and outcome of rheumatic diseases. It is a peer-reviewed publication that aims to provide the highest quality basic and clinical research in this field. The journal covers a wide range of investigative areas and also includes review articles, editorials, and educational material for researchers and clinicians. Being recognized as a leading research journal in rheumatology, Arthritis & Rheumatology serves the global community of rheumatology investigators and clinicians.